Market Intelligence, Clinical Progress, and High-Purity Reagents for Hematologic Malignancy, Oncology, and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for STAT5A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Full Length) | STAT5A Full-Length Recombinant Protein HEK293 expressed, >95% purity (SDS-PAGE), Endotoxin <1 EU/μg. Sequence Verified. Native conformation. |
View STAT5A Products |
| Antigen (Mutant) | STAT5A Y694F (Phospho-Dead) & Y694E (Phospho-Mimetic) Site-directed mutagenesis verified by sequencing. For mechanistic studies. |
View STAT5A Products |
| Antigen (Domain) | STAT5A SH2 Domain (aa 580-704) High purity for dimerization inhibitor screening. Theoretical MW verified. |
View STAT5A Products |
| Benchmark Ab/Control | Anti-STAT5A Control Antibody Recombinant positive control for western blot/assay baseline. |
View STAT5A Products |
| Selectivity Panel | STAT5B Full-Length Protein For counter-screening. >95% purity, distinct from STAT5A by Mass Spec identity. |
View STAT5B Products |
| Gene Delivery | STAT5A Premade Lentivirus (ORF & Mutants) Puro/Neo selection. For stable Ba/F3 or K562 cell line construction. |
View STAT5A Products |
| Validator | STAT5A siRNA Set (3 unique targets) For knockdown specificity verification. Sequence-verified. |
View STAT5A Products |
| Related Target | STAT3 Compensatory pathway member; resistance bypass analysis. |
View STAT3 Products |
| Related Target | JAK2 Upstream kinase; combination therapy screening. |
View JAK2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| STAT5A vs STAT5B Selectivity (96% homology in DNA-binding domain) | Purified Human STAT5A and STAT5B proteins available separately; Batch COA includes SDS-PAGE and theoretical MW confirmation; <0.5% cross-species contamination by LC-MS/MS |
| Phosphorylation-dependent Conformational Assays | Y694F (phospho-dead) and Y694E (phospho-mimetic) mutant proteins available; Sequence verified by Sanger sequencing |
| SH2 Domain Dimerization Inhibition (Small molecule screening) | Isolated SH2 domain (aa 580-704) with verified structural integrity; Suitable for SPR and crystallography |
| Cellular Target Engagement (Intracellular validation) | Lentivirus particles for stable cell line construction; Co-transfection with siRNA for specificity control |
| Lack of Structural Controls | Wild-type vs mutant paired proteins for differential binding studies |
| Intracellular Protein Conformation Assays | Native conformation preserved in recombinant expression for AlphaScreen or FP assay compatibility |
Live STAT5A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Inhibitor Research
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for STAT5A therapeutics is intensifying, with major players shifting focus from pan-STAT inhibitors to highly selective STAT5A-centric approaches, including Targeted Protein Degradation (PROTACs). As historically "undruggable" transcription factors like STAT5A become accessible, the next wave of R&D is targeting deep selectivity against STAT5B and potent intracellular engagement to combat refractory hematological malignancies.
Critical differentiation now centers on achieving therapeutic inhibition of STAT5A while sparing STAT5B, whose inhibition disrupts growth hormone signaling and lactation biology. The current landscape favors small molecule inhibitors (60%), PROTAC degraders (25%), and emerging antisense strategies (15%), with hematologic malignancies (CML, AML, mastocytosis) leading indications.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (SH2 inhibitor) | Tvardi Therapeutics, Academic Consortia, Various Biotechs | Myelofibrosis, AML, CML, Myeloproliferative Neoplasms | Selectivity Assay (Need STAT5A vs STAT5B SH2 domain proteins) |
| PROTAC / Degrader | Kymera Therapeutics, Arvinas, Emerging Biotechs | Drug-resistant leukemias, Lymphoma | Ternary Complex Formation (Need full-length STAT5A protein) |
| Antisense / RNAi / Gene Therapy | Ionis Pharmaceuticals, Alnylam | Solid tumors, Hematologic, Severe Autoimmune | Knockdown Validation (Need STAT5A-specific siRNA, antibodies, and lentivirus controls) |
| Allosteric Inhibitor | Structural Biology Groups | Inflammatory diseases | Conformational Binding (Need phospho-mimetic Y694E mutant) |